Tenascin C Antibody (DB7), Novus Biologicals™

Catalog No.	Quantity
NBP142317	0.05 mg

Catalog No. NBP142317 Supplier Novus Biologicals Supplier No. NBP142317

Description

Mouse Monoclonal Antibody

Tenascin C Monoclonal specifically detects Tenascin C in Human, Rat samples. It is validated for Western Blot, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin.

Specifications

• Antigen: Tenascin C
• Applications: Western Blot, Immunohistochemistry, Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Paraffin)
• Classification: Monoclonal
• Clone: DB7
• Concentration: 0.1 mg/mL
• Conjugate: Unconjugated
• Dilution: Western Blot 1:100-1:2000, Immunohistochemistry 1:10-1:500, Immunocytochemistry/Immunofluorescence 1:10-1:500, Immunohistochemistry-Paraffin 1:10-1:500
• Gene Alias: 150-225, Cytotactin, Glioma-associated-extracellular matrix antigen, GMEM, GP 150-225, Hexabrachion, hexabrachion (tenascin C, cytotactin), hexabrachion (tenascin), HXBcytotactin, JI, MGC167029, Myotendinous antigen, neuronectin, tenascin, tenascin C, Tenascin-C, tenascin-C isoform 14/AD1/16, TN-C, TNGP
• Gene Symbols: TNC
• Host Species: Mouse
• Immunogen: The antibody reacts with the fibrinogen-like knob-domain of tenascin protein.
• Purification Method: Protein A or G purified
• Quantity: 0.05 mg
• Regulatory Status: RUO
• Research Discipline: Cancer, Neuroscience
• Primary or Secondary: Primary
• Gene ID (Entrez): 3371
• Test Specificity: The antibody recognizes the Mr 250000 and 180000 human tenascin polypeptides in immunoprecipitation and in immunoblots the Mr 250000 polypeptide. The antibody reacts with the fibrinogen-like knob-domain of tenascin protein. The antibody reacts especially with human paraffin sections. Tenascins were first characterized in the early 1980's. Since then hundreds of publications on tenascin in normal tissues, pathologically reactive tissues and carcinomas have been published. However, only recently more elective studies have been done. In these studies retrospective material from pathology files has been studied as well as larger fresh material collected during several years from patients. These studies have now attempted to reveal more specific points in carcinogenesis and pathological tissue reactions. It has been demonstrated that tenascin immunoreactivity in breast carcinoma cells could be indicative of metastasis and survival. Recent studies using retrospective material showed that the expression of tenascin in invasion border of early breast cancer significantly correlates with higher risk of distant metastasis. These studies have been continued now and the preliminary results clearly suggest that expression of tenascin in invasion border of early breast cancer is significantly associated with proliferative activity and higher risk of local recurrence. This result implicates a wide application for tenascin antibodies in the breast pathology. The point is that tenascin expression may suggest situations in which even small breast carcinomas may need more intensive complementary therapy (chemotherapy etc.). Recent studies have also shown that tenascin is significantly increased in airway basement membrane of asthmatics and rapidly decreases by inhaled steroid. This result suggests that tenascin expression may be used to monitor the disease status and outcome of treatment in different types of asthma. The monoclonal antibody to tenascin (clone DB7) is suitable for immunohistochemistry with formalin-fixed and paraffin-embedded sections. The other monoclonal antibody (clone EB2) is highly sensitive in Western blotting. Monoclonal antibody (Mab) to tenascin is derived from the hybridoma produced by fusion between myeloma cells and Balb/c spleen cells. Tenascin polypeptides isolated from spent culture supernatant of human fibroblasts isolated by affinity chromatography were used as immunogen.
• Target Species: Human, Rat
• Content And Storage: Store at 4C. Do not freeze.
• Form: Purified
• Isotype: IgG2a

For Research Use Only